These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 1734147)

  • 1. [Drug control within the EEC II: good possibilities for Sweden].
    Strandberg K
    Lakartidningen; 1992 Jan; 89(4):178-9. PubMed ID: 1734147
    [No Abstract]   [Full Text] [Related]  

  • 2. [The Medical Products Agency's preparations prior to the new EU regulation on children and drugs].
    Johannesson M; Berglund EG
    Lakartidningen; 2007 Jul 11-24; 104(28-29):2099. PubMed ID: 17702388
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pfizer's answer to Bengt Jarhult: joint challenge to develop methods for discovery of low-frequency adverse effects].
    Dahl E; Lindstrand G
    Lakartidningen; 2005 Feb 28-Mar 6; 102(9):665. PubMed ID: 15804040
    [No Abstract]   [Full Text] [Related]  

  • 4. [Quick drug investigations; desirable, useful and steady work].
    Olofsson C
    Vardfacket; 1978 Aug; 2(15):42-5. PubMed ID: 250385
    [No Abstract]   [Full Text] [Related]  

  • 5. [Some aspects on drug safety control].
    Pekkarienen A
    Nord Med; 1967 Nov; 78(47):1539-42. PubMed ID: 6075273
    [No Abstract]   [Full Text] [Related]  

  • 6. [Children on the drug development map. The Danish Society of Clinical Pharmacology].
    Thirstrup S; Heisterberg J;
    Ugeskr Laeger; 2008 Mar; 170(12):1039. PubMed ID: 18397657
    [No Abstract]   [Full Text] [Related]  

  • 7. [Hazardous drugs, high risk patients and high risk physicians].
    Karlmark B
    Lakartidningen; 1991 Nov; 88(48):4115. PubMed ID: 1956247
    [No Abstract]   [Full Text] [Related]  

  • 8. [1992: pills without limits?].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1990 Apr; 134(16):821-7. PubMed ID: 2336124
    [No Abstract]   [Full Text] [Related]  

  • 9. Secrecy and transparency of medicines licensing in the EU.
    Abraham J; Lewis G
    Lancet; 1998 Aug; 352(9126):480-2. PubMed ID: 9708771
    [No Abstract]   [Full Text] [Related]  

  • 10. The development of good clinical practice in the EEC and in Germany.
    Anhalt E
    Methods Find Exp Clin Pharmacol; 1993 May; 15(4):217-22. PubMed ID: 8361258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug control within the EEC I: coordination during the 1990's].
    Strandberg K
    Lakartidningen; 1992 Jan; 89(3):100-1. PubMed ID: 1734132
    [No Abstract]   [Full Text] [Related]  

  • 12. [Is openness in the drug market possible?].
    Dölle W; Schwabe U
    Internist (Berl); 1986 Jan; 27(1):21-31. PubMed ID: 3514513
    [No Abstract]   [Full Text] [Related]  

  • 13. [Two years with EMEA: towards a unified drug registration within the EEC].
    Lennholm B
    Lakartidningen; 1997 Jan; 94(1-2):8-12. PubMed ID: 9053613
    [No Abstract]   [Full Text] [Related]  

  • 14. [How the Stockholm County Council works to reduce the environmental impact of drugs].
    Linusson A; Wennmalm A; Borgendahl J; Martini S
    Lakartidningen; 2010 Oct 27-Nov 2; 107(43):2664. PubMed ID: 21137541
    [No Abstract]   [Full Text] [Related]  

  • 15. [New guidelines of the European Union. Motivation for drug testing in pediatrics].
    Appel K
    Dtsch Med Wochenschr; 2001 May; 126(18):A403. PubMed ID: 11381643
    [No Abstract]   [Full Text] [Related]  

  • 16. [Communication and transparency concerning risk-benefit analysis in public health: the example of medication].
    Lehner JP; Meyer F; Juillet Y
    Therapie; 2001; 56(4):335-9. PubMed ID: 11677849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Can we rely on drug information?].
    Myhr K
    Tidsskr Nor Laegeforen; 2002 Nov; 122(27):2644-6. PubMed ID: 12523198
    [No Abstract]   [Full Text] [Related]  

  • 18. [Problems of drug safety].
    Liljestrand A
    Nord Med; 1967 Nov; 78(47):1535-9. PubMed ID: 6075272
    [No Abstract]   [Full Text] [Related]  

  • 19. Reimbursing side effects of pharmaceutical drugs--a Scandinavian speciality.
    Perman E
    J Insur Med; 1997; 29(1):36-8. PubMed ID: 10173025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Safety assessment of new products developed by the pharmaceutical industry].
    Claude JR
    Ann Pharm Fr; 2001 Sep; 59(5):324-30. PubMed ID: 11787426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.